CD4 and rheumatoid arthritis: In addition, GC treatment for this disease has been shown to reduce ANXA1 expression in CD4+ T cells in RA patients in a time‐ and concentration‐dependent manner [72] perhaps contradicting the hypothesis that ANXA1 is a downstream mediator of GCs.